October 27, 2021
Traditional industry approaches to product development can be evolved using person-generated health data (PGHD) to tailor therapeutic options based on how individuals feel and function in everyday life.
In a wide ranging conversation spanning insights from the FDA, industry trends and missed opportunities, industry experts and the team from Evidation discussed how PGHD can revolutionize evidence generation from pre-clinical development to post-market surveillance. During this recent webinar, panelists also discussed how to develop the right measures and value frameworks that capture meaningful changes to patients, and shared insights into how organizations can design, implement and manage a PGHD strategy.
How can researchers and pharma companies leverage real-world data to optimize rare disease drug discovery and development? READ MORE.
By leveraging decentralized clinical trials, what are the opportunities for data and cost savings? Since the pandemic, trials are becoming fully decentralized and virtualized. READ MORE.
FOUR CRITICAL CONSIDERATIONS FOR LAUNCHING DIGITAL DIAGNOSTIC TOOLS | Pharmaceutical Executive
FDA DRAFTS DATA STANDARDS GUIDANCE FOR RWD | Regulatory Affairs Professionals Society
NEW ALZHEIMER’S TREATMENT ADVANCES PRECISION MEDICINE | Health IT Analytics
NAVIGATING THE PATIENT MAZE – PHARMA’S EVOLVING CHALLENGE | Pharma Phorum
THOUGHT LEADERSHIP: Evidation’s co-founder and Chief Data Scientist, Luca Foschini, joined the Alldus AI in Action podcast to discuss how data curation and data quality are core to Evidation’s business. LISTEN HERE.
Luca Foschini also participated in HLTH’s panel session “The Patient Data Balancing Act” along with industry leaders from Digital Medicine Society and DataRobot. He discussed the importance of ensuring patient mediated access to data in a secure way, the challenges individuals face today and how to mitigate them in the current health care system.
RESEARCH: Obstructive sleep apnea (OSA) can lead to excessive daytime sleepiness (EDS) despite continuous positive airway pressure (CPAP) use, and is associated with a range of cardiometabolic, psychiatric, and other comorbidities. Evidation characterized the health related burden of illness associated with EDS and OSA in a recent study. READ HERE.
Evidation conducted a real-world study assessing the relationship between positive airway pressure (PAP) treatment, excessive daytime sleepiness (EDS), and patient satisfaction in patients with obstructive sleep apnea (OSA). Overall, strategies to improve patient satisfaction with OSA care should focus on PAP adherence and monitoring and resolving residual EDS. READ HERE.
October is Breast Cancer Awareness Month, so we are highlighting the importance of understanding how individuals are impacted by their diagnosis. Evidation’s researchers engaged with over 550 individuals diagnosed with breast cancer or in remission to better understand their quality of life. READ HERE.
ANNOUNCEMENTS: Evidation’s co-CEO Deb Kilpatrick was recently inducted into the UCSF Hub Hall of Fame, recognized for her continued pursuit of excellence in building innovative healthcare solutions. READ HERE.
GET TO KNOW YOUR EVIDATION TEAM: Meet Joyce Nortey, Director of Clinical Research at Evidation Health, who designs, builds and monitors Evidation’s clinical programs and helps ensure the clinical programs are being conducted according to Good Clinical Practice (GCP). READ MORE.